June 25th 2024
Durvalumab improved efficacy in patients with muscle-invasive bladder cancer.
June 17th 2024
UGN-102 also demonstrated a 79.6% complete response rate at 3 months in the phase 3 ENVISION trial.
June 3rd 2024
Patient-reported outcomes from the EV-302 trial found consistent efficacy and safety outcomes for patients with urothelial carcinoma.
Limited efficacy was observed when sacituzumab govitecan was given after enfortumab vedodin in metastatic urothelial carcinoma.
June 1st 2024
Adjuvant sacituzumab govitecan demonstrated a complete response, but its future in bladder cancer is uncertain after a recent protocol amendment.